Suppr超能文献

美国成年人阿片类药物过量风险因素与纳洛酮处方的关联

Association of Opioid Overdose Risk Factors and Naloxone Prescribing in US Adults.

作者信息

Lin Lewei Allison, Brummett Chad M, Waljee Jennifer F, Englesbe Michael J, Gunaseelan Vidhya, Bohnert Amy S B

机构信息

Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.

VA Center for Clinical Management Research (CCMR), VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.

出版信息

J Gen Intern Med. 2020 Feb;35(2):420-427. doi: 10.1007/s11606-019-05423-7.

Abstract

BACKGROUND

Prescribing naloxone to patients is a key strategy to prevent opioid overdoses, but little is known about the reach of naloxone prescribing.

OBJECTIVE

Determine patient factors associated with receiving naloxone and trends over time in patients with key overdose risk factors.

DESIGN

Retrospective observational study.

PARTICIPANTS

Using the Clinformatics DataMart, a US-wide health insurance claims dataset, we compared adults who received opioids and naloxone (opioid+naloxone) from January 2014 to June 2017 with adults who received opioids without naloxone (opioids only), matched on gender, age ± 5 years, month/year of opioid fill, and number of opioid claims.

MAIN MEASURES

Key patient-level opioid overdose risk factors included receipt of high-dosage opioids, concurrent benzodiazepines, history of opioid and other substance use disorders, and history of opioid overdose.

RESULTS

We included 3963 opioid+naloxone and 19,815 opioid only patients. Key factors associated with naloxone fills included high opioid daily dosage (50 to < 90 morphine milligram equivalents (MME): AOR = 2.43, 95% CI 2.15-2.76 and ≥ 90 MME: AOR = 3.94, 95% CI 3.47-4.46; reference: < 50 MME), receiving concurrent benzodiazepines (AOR = 1.27, 95% CI 1.16-1.38), and having a diagnosis of opioid use disorder (AOR = 1.56, 95% CI 1.40-1.73). History of opioid overdose was not associated with naloxone (AOR = 0.92, 95% CI 0.74-1.15). The percent of patients receiving naloxone increased, yet less than 2% of patients in any of the key overdose risk factor groups received naloxone by the last 6 months of the study period.

CONCLUSIONS

Naloxone prescribing has increased and was more likely to be co-prescribed to patients with some risk factors for overdose. However, overall prescribing remains minimal. Additional efforts are needed across health systems to increase naloxone prescribing for patients at risk for opioid overdose.

摘要

背景

为患者开具纳洛酮是预防阿片类药物过量的关键策略,但对于纳洛酮处方的覆盖范围了解甚少。

目的

确定与接受纳洛酮相关的患者因素以及具有关键过量风险因素患者随时间的趋势。

设计

回顾性观察研究。

参与者

使用美国范围内的医疗保险理赔数据集Clinformatics DataMart,我们将2014年1月至2017年6月期间接受阿片类药物和纳洛酮(阿片类药物+纳洛酮)的成年人与接受阿片类药物但未接受纳洛酮(仅阿片类药物)的成年人进行了比较,匹配因素包括性别、年龄±5岁、阿片类药物填充的月份/年份以及阿片类药物理赔次数。

主要测量指标

关键的患者层面阿片类药物过量风险因素包括接受高剂量阿片类药物、同时使用苯二氮卓类药物、阿片类药物和其他物质使用障碍病史以及阿片类药物过量病史。

结果

我们纳入了3963名阿片类药物+纳洛酮患者和19815名仅阿片类药物患者。与纳洛酮处方相关的关键因素包括阿片类药物每日高剂量(50至<90吗啡毫克当量(MME):调整后比值比(AOR)=2.43,95%置信区间(CI)2.15 - 2.76;≥90 MME:AOR = 3.94,95% CI 3.47 - 4.46;参考:<50 MME)、同时接受苯二氮卓类药物(AOR = 1.27,95% CI 1.16 - 1.38)以及被诊断为阿片类药物使用障碍(AOR = 1.56,95% CI 1.40 - 1.

相似文献

1
Association of Opioid Overdose Risk Factors and Naloxone Prescribing in US Adults.
J Gen Intern Med. 2020 Feb;35(2):420-427. doi: 10.1007/s11606-019-05423-7.
2
Increasing Naloxone Access and Prescribing for Patients on High-Dose Opioids From a Managed Care Pharmacy Health Plan Perspective.
J Pharm Pract. 2024 Dec;37(6):1291-1296. doi: 10.1177/08971900241247598. Epub 2024 Apr 29.
4
Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose.
JAMA Intern Med. 2024 Aug 1;184(8):954-962. doi: 10.1001/jamainternmed.2024.1733.
5
Individual and Community Factors Associated with Naloxone Co-prescribing Among Long-term Opioid Patients: a Retrospective Analysis.
J Gen Intern Med. 2021 Oct;36(10):2952-2957. doi: 10.1007/s11606-020-06577-5. Epub 2021 Feb 17.
6
Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose.
J Subst Abuse Treat. 2022 Aug;139:108785. doi: 10.1016/j.jsat.2022.108785. Epub 2022 Apr 30.
7
Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
JAMA Netw Open. 2021 Feb 1;4(2):e2036687. doi: 10.1001/jamanetworkopen.2020.36687.
8
10
Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018.
Prev Med. 2021 Dec;153:106820. doi: 10.1016/j.ypmed.2021.106820. Epub 2021 Sep 29.

引用本文的文献

1
Sleep-Disordered Breathing and Interactions with Opioids: A Narrative Review.
J Clin Med. 2025 Jul 4;14(13):4758. doi: 10.3390/jcm14134758.
2
Naloxone Prescribing Among Long-Term Opioid-Prescribed Patients: Disparities and Opportunities.
Cureus. 2025 Apr 13;17(4):e82180. doi: 10.7759/cureus.82180. eCollection 2025 Apr.
4
Iterative Development of a Clinical Decision Support Tool to Enhance Naloxone Coprescribing.
Appl Clin Inform. 2025 Jan;16(1):215-222. doi: 10.1055/a-2447-8463. Epub 2024 Oct 25.
5
Perioperative Opioid-Related Harms: Opportunities to Minimize Risk.
Semin Plast Surg. 2024 Feb 18;38(1):61-68. doi: 10.1055/s-0043-1778043. eCollection 2024 Feb.
6
Impact of 30-day prescribed opioid dose trajectory on fatal overdose risk: A population-based, statewide cohort study.
J Gen Intern Med. 2024 Feb;39(3):393-402. doi: 10.1007/s11606-023-08419-6. Epub 2023 Oct 4.
7
Evaluation of a large-scale health department naloxone distribution program: Per capita naloxone distribution and overdose morality.
PLoS One. 2023 Aug 11;18(8):e0289959. doi: 10.1371/journal.pone.0289959. eCollection 2023.
8
Preoperative risk evaluation and perioperative management of patients with obstructive sleep apnea: a narrative review.
J Dent Anesth Pain Med. 2023 Aug;23(4):179-192. doi: 10.17245/jdapm.2023.23.4.179. Epub 2023 Jul 29.
9
Opioid-induced respiratory depression and risk factors in a tertiary hospital: A retrospective study.
Saudi Pharm J. 2022 Aug;30(8):1095-1100. doi: 10.1016/j.jsps.2022.06.004. Epub 2022 Jun 13.

本文引用的文献

1
Factors associated with potentially problematic opioid prescriptions among individuals with private insurance and medicaid.
Addict Behav. 2019 Nov;98:106016. doi: 10.1016/j.addbeh.2019.06.005. Epub 2019 Jun 6.
2
Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.
JAMA Netw Open. 2019 Jun 5;2(6):e196215. doi: 10.1001/jamanetworkopen.2019.6215.
3
Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017.
JAMA Netw Open. 2019 Jun 5;2(6):e195388. doi: 10.1001/jamanetworkopen.2019.5388.
4
Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential - United States, 2003-2017.
MMWR Morb Mortal Wkly Rep. 2019 May 3;68(17):388-395. doi: 10.15585/mmwr.mm6817a3.
5
Will converting naloxone to over-the-counter status increase pharmacy sales?
Health Serv Res. 2019 Aug;54(4):764-772. doi: 10.1111/1475-6773.13125. Epub 2019 Feb 20.
7
The changing landscape of naloxone availability in the United States, 2011 - 2017.
Drug Alcohol Depend. 2018 Oct 1;191:361-364. doi: 10.1016/j.drugalcdep.2018.07.017. Epub 2018 Aug 30.
8
Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic.
Am J Public Health. 2018 Oct;108(10):1394-1400. doi: 10.2105/AJPH.2018.304590. Epub 2018 Aug 23.
9
Risks of fatal opioid overdose during the first year following nonfatal overdose.
Drug Alcohol Depend. 2018 Sep 1;190:112-119. doi: 10.1016/j.drugalcdep.2018.06.004. Epub 2018 Jul 4.
10
Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid.
Drug Alcohol Depend. 2018 Sep 1;190:37-41. doi: 10.1016/j.drugalcdep.2018.05.014. Epub 2018 Jun 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验